How Long Can You Live With Pulmonary Fibrosis?

Survival with pulmonary fibrosis depends heavily on the specific type, but the most common and aggressive form, idiopathic pulmonary fibrosis (IPF), carries a median survival of roughly three to five years from diagnosis. That number, though, is an average drawn across a wide range of individual outcomes. Some people live well beyond a decade, while others decline rapidly within a year or two. The distance between those extremes comes down to the subtype of fibrosis, how early it is caught, which treatments are available, and a handful of comorbidities that quietly accelerate the disease.

IPF Versus Other Forms of Pulmonary Fibrosis

Pulmonary fibrosis is not one disease. It is a family of conditions in which lung tissue becomes scarred and stiff, making it progressively harder to breathe. IPF is the most studied and, unfortunately, the most relentless. A real-world Japanese cohort found a median survival of 53 months from first hospital visit across all enrolled patients, with no significant difference between those over and under 70 years old.¹ Other estimates put median survival closer to three years depending on the cohort and how far along the disease was at diagnosis. The key point is that “three to five years” is a reasonable ballpark for IPF, not a fixed sentence.

Pulmonary fibrosis tied to autoimmune diseases like rheumatoid arthritis or scleroderma follows a somewhat different path. A systematic review found that when autoimmune-related lung disease takes on a progressive fibrotic pattern, median survival converges with IPF at around 3.7 years. Progression occurred in about a third of autoimmune interstitial lung disease patients overall, though the rate was higher in rheumatoid arthritis (38 to 50 percent) and scleroderma (34 percent).² In other words, once fibrosis starts behaving progressively, the underlying cause matters less than the fibrotic process itself.

Some non-IPF forms of fibrosis, such as certain drug-induced or hypersensitivity-related types, can stabilize or even partially improve if the trigger is removed early enough. Those cases can have much longer survival times. The prognosis conversation changes dramatically once fibrosis becomes self-sustaining and progressive, at which point the outlook begins to resemble IPF regardless of the original cause.

How Doctors Estimate Individual Prognosis

If you or someone you know has been diagnosed with IPF, the average survival statistic is less useful than understanding which factors push that number up or down for a specific person. The most widely used tool for this is the GAP model, which stands for Gender, Age, and Physiology. It uses those three variables along with lung function measurements to sort patients into risk stages. A large validation study found that this model performs well at predicting mortality, with a statistical accuracy measure of about 0.76 on a scale where 1.0 would be perfect prediction.³

An updated version of the model, called the Longitudinal GAP model, adds two pieces of information: whether the patient has been hospitalized for breathing problems and how quickly lung capacity has dropped over the previous six months. Adding those factors pushed the predictive accuracy higher and reclassified about a quarter of patients into more appropriate risk groups.³ The practical takeaway is that how fast your lung function is declining matters at least as much as where it started. Two patients with identical lung function today can have very different outlooks if one is declining quickly and the other is relatively stable.

A large study stratifying over 1,600 IPF patients by age found something that may surprise people: while raw survival rates were lower for those over 70, the relative survival rate (which adjusts for the fact that older people die of other causes more often) was not significantly different across age groups.⁴ Age affects how long a person lives overall, but it may not independently worsen the fibrosis itself as much as people assume.

Acute Exacerbations and Why They Matter So Much

Pulmonary fibrosis does not always follow a smooth, predictable downhill course. Many patients experience periods of relative stability interrupted by sudden, dramatic worsening called acute exacerbations. These episodes are the leading cause of death among IPF patients.⁵ During an acute exacerbation, new areas of the lung become inflamed and damaged over days to weeks, often requiring hospitalization and intensive oxygen support.

The numbers are sobering. One study found that in-hospital mortality during an acute exacerbation was 50 percent, with one- and five-year survival rates from initial IPF diagnosis of about 56 percent and 18 percent in patients who experienced these episodes.⁶ The one- and three-year incidence rates of exacerbation were roughly 14 and 21 percent respectively, meaning that a significant minority of patients will face one within a few years of diagnosis.⁶

Not all exacerbations are equally deadly. Research has shown that asymmetrical exacerbations, where the new damage appears mostly on one side of the lungs, carry a much better short-term prognosis than symmetrical ones. One study found 180-day mortality of about 31 percent for asymmetrical cases compared with 68 percent for symmetrical ones.⁷ Risk factors for having an exacerbation in the first place included lower baseline lung capacity and, interestingly, never having smoked, which may reflect differences in the underlying disease biology between smoking-related and non-smoking-related IPF.

How Antifibrotic Drugs Extend Survival

Two antifibrotic medications, pirfenidone and nintedanib, have become the backbone of IPF treatment over the past decade. Neither drug cures pulmonary fibrosis or reverses existing scarring. What they do is slow the rate at which the lungs lose function. A real-world comparison study found that after one year of antifibrotic therapy, the rate of lung capacity decline slowed significantly compared with the pre-treatment period.⁸

Data from the Czech national registry showed that nintedanib-treated patients had significantly longer overall survival than those receiving no antifibrotic therapy, with a roughly 55 percent reduction in mortality risk over a two-year follow-up.⁹ In the Japanese cohort receiving long-term antifibrotic treatment (one year or more), two- and five-year survival probabilities were about 89 percent and 52 percent respectively, a considerable improvement over older historical averages.¹

A systematic review and meta-analysis found that the two drugs performed similarly in slowing lung function decline, and that their effectiveness held up whether the underlying condition was IPF or non-IPF progressive fibrosis.¹⁰ That finding supports the idea that progressive fibrosis shares a common pathway regardless of its trigger, which is why antifibrotics now have broader approvals beyond IPF alone.

Lung Transplantation

For patients whose disease progresses despite medication, lung transplantation remains the only intervention that can dramatically extend life. A study of single lung transplants for pulmonary fibrosis found survival rates of about 83 percent at one year, 59 percent at five years, and 29 percent at ten years.¹¹ Outcomes have been improving over time. A large analysis of the transplant registry found that one-year survival rose from about 80 percent in 2005 to around 90 percent by 2020, with five-year survival increasing from roughly 52 to 55 percent across eras.¹²

Transplantation is not available to everyone. Age limits, other health conditions, lack of donor organs, and the demands of lifelong immunosuppression all narrow the pool of candidates. Pulmonary fibrosis is, however, now the leading indication for lung transplant in many countries, which means transplant programs have significant experience managing these patients. If your pulmonologist has not discussed transplant evaluation, it is worth asking whether you might be a candidate, especially while you are still well enough to go through the process.

Comorbidities That Shorten Survival

Certain conditions that develop alongside pulmonary fibrosis can dramatically worsen the outlook. Pulmonary hypertension, or high blood pressure in the arteries of the lungs, is the most dangerous companion. Data from the European IPF Registry found that patients with pulmonary hypertension had a median survival of 2.85 years, and multivariate analysis confirmed pulmonary hypertension as an independent predictor of death with roughly double the mortality risk.¹³ Another study looking specifically at advanced IPF found that one-year mortality was 28 percent in patients with pulmonary arterial hypertension versus about 6 percent without it.¹⁴

Acid reflux is another condition that has gained attention. Gastroesophageal reflux is extremely common in IPF patients, often without the typical heartburn symptoms. The concern is that tiny amounts of stomach contents can be aspirated into the lungs, causing repeated low-grade injury that fuels fibrosis progression.¹⁵ Research has linked acid reflux and the detection of stomach enzymes in lung fluid to more severe lung impairment and potentially even to triggering acute exacerbations.¹⁶ Some data suggest that treating reflux with acid-suppressing medications may slow the decline in lung function, though this remains an area of active research rather than a settled conclusion.¹⁵

Why Getting Diagnosed Early Changes the Timeline

One of the most frustrating aspects of pulmonary fibrosis is that it often goes unrecognized for months or years. Early symptoms like a dry cough and mild breathlessness are easy to attribute to aging, allergies, or being out of shape. By the time imaging or lung function testing catches up, significant scarring may already be present. That delay has real consequences.

A study found that patients whose diagnosis was delayed by more than one year had significantly worse progression-free survival compared with those diagnosed more quickly. The median time to disease progression or death was 15 months for those with a long diagnostic delay versus 36 months for those diagnosed promptly. The effect was strongest in patients who still had relatively preserved lung function at diagnosis, where the delay more than doubled the risk of progression.¹⁷ Delayed diagnosis was also linked to higher hospitalization rates, particularly in the first year after finally being diagnosed.¹⁷

Separate research confirmed that delayed referral to a specialized center is independently associated with higher mortality, even after accounting for disease severity.¹⁸ If you have a persistent unexplained cough or progressive shortness of breath, pushing for a referral to a pulmonologist sooner rather than later is one of the most consequential things you can do.

Pulmonary Rehabilitation and Muscle Mass

Pulmonary rehabilitation, a structured exercise and education program, does not directly treat lung scarring, but it meaningfully improves quality of life and appears to extend survival. A propensity-matched study comparing IPF patients who completed rehabilitation with those who did not found that failing to complete the program was associated with a more than five-fold increase in the risk of dying within a year.¹⁹ Among IPF patients awaiting lung transplantation, those who completed a rehabilitation program had a cumulative survival of about 90 percent during follow-up compared with 63 percent among controls, representing a roughly 54 percent reduction in the risk of death.²⁰

Related to this is the emerging recognition that muscle wasting, or sarcopenia, is a powerful predictor of worse outcomes in IPF. Multiple studies have found that patients with low muscle mass have substantially shorter survival. One study reported median survival of just 19 months in IPF patients with sarcopenia compared with 61 months without it. Another found that sarcopenia carried nearly a five-fold increase in the risk of adverse outcomes within 12 months.²¹ Maintaining muscle mass through regular activity and adequate nutrition is not glamorous advice, but it may be one of the most impactful things a patient can do alongside taking prescribed medications.

Genetic Clues and CT Scan Patterns

Researchers have been working to identify biological markers that predict who will progress faster. Two have emerged repeatedly across studies: a common genetic variant in the MUC5B gene and telomere length (the protective caps on the ends of chromosomes that shorten with aging and cellular stress).

In patients with chronic hypersensitivity pneumonitis, a condition that can lead to progressive fibrosis, carriers of the MUC5B risk variant and those with shorter telomeres independently had more extensive lung scarring on imaging. Shorter telomere length was also associated with worse survival, with an adjusted hazard ratio indicating substantially higher mortality risk.²² A Chinese IPF cohort found similar patterns: certain MUC5B variants were linked to more extensive honeycombing on CT scans and shorter overall survival.²³

On imaging, honeycombing, a pattern of clustered air-filled cysts visible on CT scans, is one of the hallmarks of advanced fibrosis and carries prognostic weight of its own. In scleroderma-related lung disease, honeycombing was present in roughly 37 to 42 percent of patients and was associated with significantly higher mortality, with hazard ratios ranging from about 1.7 to 4.6 depending on the study.²⁴ These markers are not yet part of routine clinical decision-making for most patients, but they may eventually help personalize treatment plans and identify people who need more aggressive intervention earlier.

The Role of Palliative Care

Palliative care is one of the most misunderstood aspects of managing pulmonary fibrosis. Many people associate it exclusively with dying, but in practice it focuses on controlling symptoms like breathlessness, cough, and anxiety at every stage of the disease. Studies have shown that integrating palliative care early alongside other treatments can improve symptom management, quality of life, and reduce hospitalizations and health costs.²⁵ Research has also found that many IPF patients do not receive palliative care until very late in their disease course, and that earlier referral is consistently recommended in the literature.²⁶

Palliative care teams can help with supplemental oxygen optimization, manage side effects from antifibrotic drugs, address the psychological burden of living with a progressive disease, and facilitate advance care planning so that patients’ wishes are respected if their condition deteriorates suddenly. Asking for a palliative care referral does not mean giving up on treatment. It means getting a team whose entire focus is making you more comfortable while you continue treating the disease itself.

New Therapies on the Horizon

The current antifibrotic drugs were a genuine breakthrough, but they slow the disease rather than stopping it. Researchers are pursuing therapies that target different points in the scarring process. The underlying mechanism involves lung cells transforming into scar-producing cells called myofibroblasts under the influence of various chemical signals. Multiple signaling pathways drive this transformation, and blocking just one or two of them, which is what existing drugs do, leaves others active.²⁷

A new drug called nerandomilast has recently been approved, and several other agents are in late-stage clinical trials targeting novel pathways.²⁸ Meanwhile, home spirometry devices are being studied as a way to catch declines in lung function earlier than traditional clinic visits would, which could allow treatment adjustments before significant damage accumulates.²⁹ The combination of better drugs, earlier detection of progression, and the growing use of combination therapy strategies makes the outlook for newly diagnosed patients meaningfully better than it was even five years ago.

1
MDPI (Journal of Clinical Medicine). A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly – Section: Survival Probabilities of All Enrolled Patients
2
Revista Colombiana de Reumatología. Progressive pulmonary fibrosis associated autoimmune diseases: Systematic review of the literature – Section: Results
3
European Respiratory Journal. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis – Section: Abstract
4
PubMed Central. Relationship between survival and age in patients with idiopathic pulmonary fibrosis – Section: Abstract
5
PubMed Central. Acute exacerbation of idiopathic pulmonary fibrosis: who to treat, how to treat. – Section: Abstract
6
PubMed. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
7
PubMed Central. Asymmetry in acute exacerbation of idiopathic pulmonary fibrosis
8
PubMed Central. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study – Section: Results
9
PubMed Central. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry – Section: RESULTS
10
PubMed Central. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis – Section: INTERPRETATION
11
JHLT Open. Single lung transplantation for pulmonary fibrosis: Does side matter? – Section: Results
12
The Annals of Thoracic Surgery. Lung Transplant Outcomes for Idiopathic Pulmonary Fibrosis: Are We Improving? – Section: Results
13
PubMed Central. Pulmonary Hypertension Drives Prognosis in Idiopathic Pulmonary Fibrosis: Insights from the European IPF Registry – Section: Results
14
PubMed. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis – Section: MEASUREMENTS AND RESULTS
15
PubMed Central. The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis – Section: Abstract
16
European Respiratory Journal. Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?
17
BMJ Open Respiratory Research. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates – Section: Results
18
PubMed Central. Delayed Access and Survival in Idiopathic Pulmonary Fibrosis: A Cohort Study – Section: Conclusions
19
PubMed Central. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study – Section: Results
20
Scientific Reports. Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation – Section: Results
21
PubMed Central. Sarcopenia in idiopathic pulmonary fibrosis: an updated systematic review and meta-analysis – Section: 3.5 Impact of sarcopenia on pulmonary function, exercise capacity, and clinical outcomes in IPF patients
22
PubMed Central. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis – Section: Results
23
Scientific Reports. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort – Section: Results
24
The Indonesian Journal of General Medicine. A RELATIONSHIP BETWEEN THE HONEYCOMB APPEARANCE ON CT SCAN AND LIFE EXPECTANCY IN PATIENTS WITH SCLERODERMA? A SYSTEMATIC REVIEW – Section: Results
25
PubMed Central. Palliative care and end of life management in patients with idiopathic pulmonary fibrosis – Section: Abstract
26
PubMed Central. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis – Section: Abstract
27
PubMed Central. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis – Section: Abstract
28
PubMed Central. Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways
29
BMJ Open Respiratory Research. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease – Section: Methods and analysis